<?xml version="1.0" encoding="UTF-8"?>
<p id="Par18">All 54 HBV-infected patients receiving antiviral therapy had a negative HBV–DNA; of these, 20 (37,0%) were receiving lamivudine + adefovir, 20 (37,0%) tenofovir, 2 (3,7%) lamivudine monotherapy and 12 (22,2%) entecavir monotherapy. Among NAs treated patients, only 1/54 (4.5%) had a compensated cirrhosis (Child Pugh A) and 5/54 (9.2%) complained of therapy-related asthenia.</p>
